Trial Profile

Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CX 1739 (Primary) ; Remifentanil
Indications Respiratory insufficiency
Focus Therapeutic Use
Sponsors RespireRx Pharmaceuticals

Most Recent Events

08 Jan 2018 According to a RespireRx Pharmaceuticals media release, data from this trial will be presented at The Biotech Showcase 2018.
08 Sep 2017 According to a RespireRx Pharmaceuticals media release, results from this trial will be presented at the 2017 Rodman & Renshaw Conference.
14 Jun 2017 According to a RespireRx Pharmaceuticals media release, results from this trial will be presented at the 2017 Marcum MicroCap Conference 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com